67 results on '"Carpen, Olli"'
Search Results
2. Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
3. Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
4. Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
5. Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
6. Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
7. Supplementary Data from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
8. Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
9. Supplementary Data from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
10. Supplementary Table from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
11. Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
12. Supplementary Table from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
13. Supplementary Table from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
14. Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
15. Supplementary Table from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
16. A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer
17. Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
18. FinnGen: Unique genetic insights from combining isolated population and national health register data
19. A single-cell atlas of human fetal lung development between 14 and 19 weeks of gestation
20. Peripheral neuropathy linked mRNA export factor GANP reshapes gene regulation in human motor neurons
21. Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype
22. Abstract B62: Integrating highly-multiplexed imaging with multi-omics data to uncover immunologic vulnerabilities in high-grade serous ovarian cancer
23. The Palladin/Myotilin/Myopalladin Family of Actin‐Associated Scaffolds
24. Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer–Associated CA125 from Benign Sources
25. Novel Molecular Interactions and Biological Functions of the Neurofibromatosis 2 Tumor Suppressor Protein, Merlin
26. Abstract B70: Mathematical model quantifies the effect of novel combination therapies in high-grade serous ovarian cancer
27. Abstract B40: High-throughput screening of new potential targets for high-grade serous ovarian cancer treatment
28. Abstract 5344: Phylogenetic and signature analyses predict treatment response in high-grade serous ovarian cancer
29. Abstract 875: Chemical biology approach to phenotypic intra-tumor heterogeneity in high-grade serous ovarian cancer
30. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma
31. AB040. P011. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma
32. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma
33. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells
34. A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis
35. Circulating tumor DNA analysis using targeted sequencing of 508 clinically actionable genes in patients with high grade serous ovarian cancer.
36. Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors
37. EGFRgene copy number predicts response to anti-EGFR treatment inRASwild type andRAS/BRAF/PIK3CAwild type metastatic colorectal cancer
38. A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources
39. EGFR gene copy number to predict response to anti-EGFR treatment and survival in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
40. REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker
41. N-glycomic Profiling as a Tool to Separate Rectal Adenomas from Carcinomas*
42. Actin-associated protein palladin promotes tumor cell invasion by linking extracellular matrix degradation to cell cytoskeleton
43. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry
44. Palladin promotes assembly of non-contractile dorsal stress fibers through VASP recruitment
45. Distribution of Prolyl Oligopeptidase in Human Peripheral Tissues and in Ovarian and Colorectal Tumors
46. Neurofibromatosis 2011: a report of the Children’s Tumor Foundation Annual Meeting
47. Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer
48. Analysis of myotilin turnover provides mechanistic insight into the role of myotilinopathy-causing mutations
49. Expression of ezrin, Bcl-2, and Ki-67 in chondrosarcomas
50. A Class III PDZ Binding Motif in the Myotilin and FATZ Families Binds Enigma Family Proteins: a Common Link for Z-Disc Myopathies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.